Essex Bio-Technology Limited

SEHK:1061 주식 보고서

시가총액: HK$1.5b

Essex Bio-Technology 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Haizhou Fang

최고 경영자

HK$1.7m

총 보상

CEO 급여 비율97.5%
CEO 임기no data
CEO 소유권0.9%
경영진 평균 재임 기간23.8yrs
이사회 평균 재임 기간4.2yrs

최근 관리 업데이트

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06
Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Mar 21
Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Dec 07
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Aug 25
Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Jun 22
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30
Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31
Is Essex Bio-Technology (HKG:1061) A Risky Investment?

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13
If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04
Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23
Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

CEO 보상 분석

Haizhou Fang 의 보수는 Essex Bio-Technology 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

HK$263m

Mar 31 2024n/an/a

HK$269m

Dec 31 2023HK$2mHK$2m

HK$275m

Sep 30 2023n/an/a

HK$266m

Jun 30 2023n/an/a

HK$256m

Mar 31 2023n/an/a

HK$241m

Dec 31 2022HK$2mHK$2m

HK$225m

Sep 30 2022n/an/a

HK$274m

Jun 30 2022n/an/a

HK$323m

Mar 31 2022n/an/a

HK$334m

Dec 31 2021HK$2mHK$2m

HK$346m

Sep 30 2021n/an/a

HK$339m

Jun 30 2021n/an/a

HK$332m

Mar 31 2021n/an/a

HK$275m

Dec 31 2020HK$2mHK$2m

HK$219m

Sep 30 2020n/an/a

HK$221m

Jun 30 2020n/an/a

HK$222m

Mar 31 2020n/an/a

HK$262m

Dec 31 2019HK$2mHK$737k

HK$303m

Sep 30 2019n/an/a

HK$282m

Jun 30 2019n/an/a

HK$262m

Mar 31 2019n/an/a

HK$246m

Dec 31 2018HK$2mHK$766k

HK$231m

Sep 30 2018n/an/a

HK$210m

Jun 30 2018n/an/a

HK$189m

Mar 31 2018n/an/a

HK$178m

Dec 31 2017HK$2mHK$721k

HK$167m

보상 대 시장: Haizhou 의 총 보상 ($USD 224.31K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 359.96K ).

보상과 수익: Haizhou 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Haizhou Fang (58 yo)

no data

테뉴어

HK$1,744,587

보상

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...

리더십 팀

이름위치테뉴어보상소유권
Mia Je Ngiam
Founder & Chairmanno dataHK$3.23m52.75%
HK$ 805.1m
Haizhou Fang
MD & Executive Directorno dataHK$1.74m0.92%
HK$ 14.1m
Hian Leng Ngiam
Executive Director & Deputy MDno dataHK$1.80m0.36%
HK$ 5.5m
Lai Man Yau
Executive Director & Company Secretary23.8yrsHK$755.60k0.0081%
HK$ 123.8k
Qi Xue
Group Chief Scientific Officer6.6yrs데이터 없음데이터 없음

23.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: 1061 의 관리팀은 노련하고 경험 (평균 재직 기간 23.8 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Mia Je Ngiam
Founder & Chairmanno dataHK$3.23m52.75%
HK$ 805.1m
Haizhou Fang
MD & Executive Directorno dataHK$1.74m0.92%
HK$ 14.1m
Hian Leng Ngiam
Executive Director & Deputy MD4.2yrsHK$1.80m0.36%
HK$ 5.5m
Lai Man Yau
Executive Director & Company Secretary4.2yrsHK$755.60k0.0081%
HK$ 123.8k
Chi Ying Fung
Independent Non Executive Director23.4yrsHK$250.00k데이터 없음
Mee Mooi Yeow
Independent Non Executive Director20.2yrsHK$220.00k데이터 없음
Man Sing Yan
Independent Non-Executive Director1.4yrsHK$128.33k데이터 없음

4.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 1061 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.